Completed PHASE1 INTERVENTIONAL 1-arm NCT01263327

Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years

Sponsor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Conditions Cervical Cancer

Interventions HPV 16/18

Updated 8 times since 2017 Last updated: Jul 9, 2020 Started: Dec 31, 2010 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cervical Cancer and is currently completed. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2024 — Feb 2024 [monthly]

Completed PHASE1
Jan 2021 — Jan 2024 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Aug 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2020 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Xiamen Innovax Biotech Co., Ltd
Xiamen University

Data source: Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dongtai, China